BAILEY ZARUBA: Open Payments
NPI 1053099051 · CEDAR RAPIDS, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,548 in 88 payments from 16 companies in 2025. Trend: 2023 $187 · 2024 $842 · 2025 $1,548
Food & beverage: $1,548
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $260 |
| Otsuka America Pharmaceutical, Inc. | 12 | $251 |
| Supernus Pharmaceuticals, Inc. | 10 | $158 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $157 |
| Teva Pharmaceuticals USA, Inc. | 7 | $136 |
| Neurocrine BioSciences, Inc. | 7 | $123 |
| Alkermes, Inc. | 6 | $115 |
| Lundbeck LLC | 4 | $95 |
| Janssen Pharmaceuticals, Inc | 3 | $57 |
| HARMONY BIOSCIENCES LLC | 2 | $40 |
Products named: VRAYLAR, REXULTI, Qelbree, CAPLYTA, INGREZZA, ARISTADA, ABILIFY ASIMTUFII, AUSTEDO XR.
Industry payments across IA — which companies pay providers there.
